Aberrant changes in growth factor processes can lead to abnormal cell growth and cancer and tumor formation. Malignancy can be triggered via the unregulated expression of growth factors and there corollary signaling pathways.
Different methods of targeting growth factor related cancer formation may be indicated including antagonists, monoclonal antibodies , receptor inhibitors, protein tyrosine kinase inhibition and cell transcription pathway interventions.
|
|
FFPE Normal human kidney , stained with IGF-1 clone 7973 at 1ug/ml
| Primary Description: | Mouse Anti-Insulin-Like Growth Factor [7973] |
| Product Reference Code: | IQ391 |
| Species Reactivity: | Human, Mouse, Rat |
| Applications: | RIA, ELISA, IHC(Fr), IHC(P) |
£226.00
![Insulin Like Growth Factor Antibody [7973]](/images/products/thumbnails/1315227354-72694600.jpg)
| Primary Description: | Mouse Anti-Parathyroid Hormone Receptor 1 [3D1.1] |
| Product Reference Code: | IQ393 |
| Species Reactivity: | Human |
| Applications: | ELISA, Flow Cytometry, WB, IHC(P) |
£226.00
![Parathyroid Hormone Receptor 1 Antibody [3D1.1]](/images/products/thumbnails/1301567534-89071900.jpg)
| Primary Description: | Mouse Anti-Human TGF beta1 [TB21] |
| Product Reference Code: | IQ159 |
| Species Reactivity: | Human |
| Applications: | ELISA, IHC(Fr), IHC(P), WB |
£226.00
![TGF beta1 Antibody [TB21]](/images/products/thumbnails/1304501186-78324900.png)
